DR-385 Development of computational multi-omics strategies for targeting therapeutically the tumour metastasis and tumour microenvironment heterogeneity

Identifying the most appropiate therapies based on cancer genome data is a major challenge in personalized cancer medicine. Physicians and researchers face with long lists of tumor-specific genomic variants where most variants are either clinically “unactionable”, their biological role unknown or they are irrelevant for tumor biology. Our group develops novel bioinformatics methods to interpret tumoral multi-omics alterations, evaluate their clinical relevance and drug feasibility and provide a prioritized evidence-based list of tailored anticancer therapies to facilitate clinical decision making.

Fátima Al-Shahrour, Spanish National Cancer Research Center (CNIO), Spain